Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/198314ANTIBODIES BINDING TO O-LINKED CARBOHYDRATES ON SARS-COV-2 SPIKE PROTEIN AND USES THEREOF
WO 29.09.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CA2022/050426 Applicant KORANEX CAPITAL Inventor MOFFETT, Serge
A protein complex comprising a SARS-CoV-2 S protein or fragment thereof, expressing one or more carbohydrate antigens, bound to a recombinant ligand having binding specificity for said carbohydrate antigen, is described herein. The carbohydrate antigen may be an O-linked carbohydrate antigen, such as unsialylated Thomsen-Friedenreich (TF) antigen, sialylated TF antigen, unsialylated Tn antigen, sialylated Tn antigen, or any combination thereof. The ligand may be a recombinant antibody or an antigen-binding fragment thereof. Also described herein is the use of such a recombinant ligand for binding to a SARS-CoV-2 S protein or fragment thereof, for treating or reducing the risk of SARS-CoV-2 viral infection in a subject.
2.WO/2022/193017ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
WO 22.09.2022
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/CA2022/050400 Applicant ADMARE THERAPEUTICS SOCIETY Inventor CUMMINS, Emma J.
Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.
3.WO/2022/197840ADENOVIRUS SARS-COV-2 VACCINE
WO 22.09.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2022/020604 Applicant THE WISTAR INSTITUTE Inventor ERTL, Hildegund, C., J.
The present invention includes methods and compositions useful for treating or preventing a coronavirus infection in a subject. In certain embodiments the treatment comprises adenoviral-based vaccines against SARS-CoV-2 viral proteins.
4.WO/2022/192163NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF
WO 15.09.2022
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
Appl.No PCT/US2022/019222 Applicant PURDUE RESEARCH FOUNDATION Inventor JAGANNATH, Chinnaswamy
The present invention discloses a recombinant adenovirus vector of a replication-defective human adenovirus (HAdv85C5) or a bovine adenovirus (BAdv85C5) comprising a recombinant adenovirus vector having a heterologous DNA segment encoding mycobacterial Ag85B-p25 epitope (SEQ ID NO: 1), mycobacterial Ag85B-p25 epitope fusion of autophagy-inducing peptide-C5 (SEQ ID NO: 2), or a substantially homologous functional fragment thereof. The vector, having a heterologous DNA segment of SEQ ID NO: 3, SEQ ID NO: 4, or a substantially homologous functional fragment thereof, is an effective vaccine for therapeutically or prophylactically immunizing a subject for protection of infections by various microorganisms, especially Mycobacterium tuberculosis (Mtb), which causes the widespread tuberculosis. Methods of uses and pharmaceutical composition matters are within the scope of this disclosure.
5.20220289828HUMAN MONOCLONAL ANTIBODIES TO ENTEROVIRUS D68
US 15.09.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17630053 Applicant VANDERBILT UNIVERSITY Inventor JAMES E. CROWE, Jr.

The present disclosure is directed to antibodies binding to enterovirus D68 (EV-D68) and methods for use thereof.

6.WO/2022/192740NEUTRALIZING MONOCLONAL ANTIBODIES TO BK VIRUS
WO 15.09.2022
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2022/020050 Applicant ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Inventor MORAN, Thomas, M.
Provided herein are monoclonal antibodies targeting VP1 of polyomaviruses including BK virus. Also provided are methods of treating or preventing polyomavirus infections using one or more antibodies.
7.20220289829ANTI-HIV VACCINE ANTIBODIES WITH REDUCED POLYREACTIVITY
US 15.09.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17625247 Applicant California Institute of Technology Inventor Stuart A. Sievers

This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.

8.WO/2022/188829SARS-COV-2 ANTIBODY AND APPLICATION THEREOF
WO 15.09.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2022/080100 Applicant SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Inventor LI, Li
A SARS-CoV-2 antibody and an application thereof. Provided is an antibody or an antigen-binding fragment thereof that specifically binds to a receptor-binding domain (RBD) of SARS-CoV-2 or a variant thereof. Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and a therapeutic and diagnostic method and an application of the antibody or the antigen-binding fragment thereof.
9.115043933靶向新冠病毒的纳米抗体及其制备方法和应用
CN 13.09.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202210637519.5 Applicant 深圳市人民医院 Inventor 孙继超
本发明实施例公开了一种靶向新冠病毒的纳米抗体及其制备方法和应用,所述纳米抗体包括纳米抗体NbN2、纳米抗体NbN3、纳米抗体NbN4、纳米抗体NbN5、纳米抗体NbN6、纳米抗体NbN11中的至少一种,提供的纳米抗体对新冠病毒野生株、新冠病毒变异株阿尔法(Alpha)、新冠病毒贝塔(Beta)、新冠病毒德尔塔(Delta)、新冠病毒Omicron及其亚型BA.2的RBD结构域具有较高的亲和力,能够快速且特异性地中和不同的新冠病毒,有效抑制其活性;同时,提供的纳米抗体具有更长的CDR3序列,有利于纳米抗体进行灵活调节其构象,提高与病毒的结合作用,有利于广泛应用。
10.115043935靶向新冠病毒的纳米抗体及其制备方法和应用
CN 13.09.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202210637547.7 Applicant 深圳市人民医院 Inventor 杨传彬
本发明实施例公开了一种靶向新冠病毒的纳米抗体及其制备方法和应用,所述纳米抗体包括纳米抗体NbN2、纳米抗体NbN3、纳米抗体NbN4、纳米抗体NbN5、纳米抗体NbN6、纳米抗体NbN11中的至少一种,提供的纳米抗体对新冠病毒野生株、新冠病毒变异株阿尔法(Alpha)、新冠病毒贝塔(Beta)、新冠病毒德尔塔(Delta)、新冠病毒Omicron及其亚型BA.2的RBD结构域具有较高的亲和力,能够快速且特异性地中和不同的新冠病毒,有效抑制其活性;同时,提供的纳米抗体具有更长的CDR3序列,有利于纳米抗体进行灵活调节其构象,提高与病毒的结合作用,有利于广泛应用。